



May 24, 2014

## **BioCryst to Announce Results From the BCX4161 OPuS-1 Phase 2 Trial for Hereditary Angioedema May 27**

RESEARCH TRIANGLE PARK, N.C., May 24, 2014 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#), (Nasdaq:BCRX) today announced that management plans to report results for the [OPuS-1](#) (Oral Prophylaxis-1) proof of concept Phase 2a clinical trial of orally-administered [BCX4161](#) in patients with hereditary angioedema (HAE) the morning of Tuesday, May 27, 2014. BioCryst will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the trial results.

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at <http://investor.shareholder.com/biocryst/events.cfm>.

### **About BioCryst Pharmaceuticals**

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in infectious and rare diseases, with the goal of addressing unmet medical needs of patients and physicians. BioCryst's core development programs include BCX4161 and two next generation oral inhibitors of plasma kallikrein for hereditary angioedema; [peramivir](#), a viral neuraminidase inhibitor for the treatment of influenza; and [BCX4430](#), a broad spectrum antiviral for hemorrhagic fevers. For more information, please visit the Company's website at [www.BioCryst.com](http://www.BioCryst.com).

BCRXW

CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910



Source: BioCryst Pharmaceuticals

News Provided by Acquire Media